The immunologic basis for hepatitis C infection

Current Opinion in Gastroenterology

Volumn 20, Issue 6, 2004, Pages 598-602

  Sun, Jiaren ^a,b   Li, Kui ^a,d   Shata, Mohamed Tarek ^c   Chan, Teh Sheng ^a  

^a UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^b University of Texas Medical Branch School of Medicine   (United States)

^c UNIVERSITY OF CINCINNATI   (United States)

^d American Liver Foundation   (United States)

Author keywords

Cytotoxic T lymphocytes; Hepatitis C virus; Immune responses; Liver; Viral hepatitis

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; GAMMA INTERFERON; INTERLEUKIN 2; MAJOR HISTOCOMPATIBILITY ANTIGEN; TUMOR NECROSIS FACTOR ALPHA; VIRUS RNA;

ANTIGEN RECOGNITION; CELL DESTRUCTION; CELL PROLIFERATION; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; DENDRITIC CELL; GENE MUTATION; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IMMUNE MEDIATED INJURY; IMMUNE RESPONSE; IMMUNOPATHOGENESIS; LIVER CELL; LIVER INJURY; MAJOR HISTOCOMPATIBILITY COMPLEX; NATURAL KILLER CELL; NONHUMAN; PERSISTENT VIRUS INFECTION; REVIEW; T LYMPHOCYTE; TH1 CELL; VIRUS ACTIVATION; VIRUS GENE;

EID: 7444256118     PISSN: 02671379     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001574-200411000-00016     Document Type: Review

References (68)

1. Bain VG, Wong WW, Greig PD, et al.: Hepatology and the Canadian gastroenterologist: interest, attitudes and patterns of practice: results of a national survey from the Canadian Association of Gastroenterology. Can J Gastroenterol 2003, 17:25-29.
2. Alter MJ, Kruszon-Moran D, Nainan OV, et al.: The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 1999, 341:556-562.
3. Bronowicki JP, Venard V, Bottâe C, et al.: Patient-to-patient transmission of hepatitis C virus during colonoscopy. N Engl J Med 1997, 337:237-240.
4. Lamarre D, Anderson PC, Bailey M, et al.: An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus. Nature 2003, 426:186-189. Administration of a novel HCV NSS protease inhibitor to patients infected with HCV genotype 1 resulted in an impressive reduction of viremia, and established proof-of-concept for a viral-enzyme-targeted drug in humans.
5. Di Bisceglie AM, McHutchison J, Rice CM: New therapeutic strategies for hepatitis C. Hepatology 2002, 35:224-231.
6. Lauer GM, Walker BD: Hepatitis C virus infection. N Engl J Med 2001, 345:41-52.
7. Shata MT, Anthony DD, Carlson NL, et al.: Characterization of the immune response against hepatitis C infection in recovered, and chronically infected chimpanzees. J Viral Hepat 2002, 9:400-410.
8. Shoukry NH, Grakoui A, Houghton M, et al.: Memory CD8+ T cells are required for protection from persistent hepatitis C virus infection. J Exp Med 2003, 197:1645-1655. Depletion of CD8+ T cells upon viral rechallenge resulted in prolonged HCV replication. These results demonstrate an undisputable role for memory CD8+ T cells in long-term protection from chronic hepatitis C.
9. Lechner F, Wong DK, Dunbar PR, et al.: Analysis of successful immune responses in persons infected with hepatitis C virus. J Exp Med 2000, 191: 1499-1512.
10. Grakoui A, Shoukry NH, Woollard DJ, et al.: HCV persistence and immune evasion in the absence of memory T cell help. Science 2003, 302:659-662. Antibody-mediated depletion of CD4+ T cells in two HCV-infected chimpanzees resulted in emergence of viral escape mutations and prolonged disease. These results suggest a unique role for memory CD4+ Th cells in suppressing viral evasion and disease resolution.
11. Tsai SL, Liaw YF, Chen MH, et al.: Detection of type 2-like T-helper cells in hepatitis C virus infection: implications for hepatitis C virus chronicity. Hepatology 1997, 25:449-458.
12. Thimme R, Oldach D, Chang KM, et al.: Determinants of viral clearance and persistence during acute hepatitis C virus infection. J Exp Med 2001, 194:1395-1406.
13. Thimme R, Bukh J, Spangenberg HC, et al.: Viral and immunological determinants of hepatitis C virus clearance, persistence, and disease. Proc Natl Acad Sci USA 2002, 99:15661-15668.
14. Frese M, Schwèarzle V, Barth K, et al.: Interferon-gamma inhibits replication of subgenomic and genomic hepatitis C virus RNAs. Hepatology 2002, 35:694-703.
15. Bigger CB, Brasky KM, Lanford RE: DNA microarray analysis of chimpanzee liver during acute resolving hepatitis C virus infection. J Virol 2001, 75:7059-7066.
16. Su AI, Pezacki JP, Wodicka L, et al.: Genomic analysis of the host response to hepatitis C virus infection. Proc Natl Acad Sci USA 2002, 99:15669-15674.
17. Betts MR, Price DA, Brenchley JM, et al.: The functional profile of primary human antiviral CD8+ T cell effector activity is dictated by cognate peptide concentration. J Immunol 2004, 172:6407-6417.
18. Gruener NH, Lechner F, Jung MC, et al.: Sustained dysfunction of antiviral CD8+ T lymphocytes after infection with hepatitis C virus. J Virol 2001, 75:5550-5558.
19. Kantzanou M, Lucas M, Barnes E, et al.: Viral escape and T cell exhaustion in hepatitis C virus infection analysed using Class I peptide tetramers. Immunol Lett 2003, 85:165-171.
20. Sarobe P, Lasarte JJ, Casares N, et al.: Abnormal priming of CD4(+) T cells by dendritic cells expressing hepatitis C virus core and E1 proteins. J Virol 2002, 76:5062-5070.
21. Laporte J, Bain C, Maurel P, et al.: Differential distribution and internal translation efficiency of hepatitis C virus quasispecies present in dendritic and liver cells. Blood 2003, 101:52-57.
22. Goutagny N, Fatmi A, De Ledinghen V, et al.: Evidence of viral replication in circulating dendritic cells during hepatitis C virus infection. J Infect Dis 2003, 187:1951-1958.
23. Goutagny N, Vieux C, Decullier E, et al.: Quantification and functional analysis of plasmacytoid dendritic cells in patients with chronic hepatitis C virus infection. J Infect Dis 2004, 189:1646-1655.
24. Sugimoto K, Ikeda F, Stadanlick J, et al.: Suppression of HCV-specific T cells without differential hierarchy demonstrated ex vivo in persistent HCV infection. Hepatology 2003, 38:1437-1448.
25. Suvas S, Azkur AK, Kim BS, et al.: CD4(+)CD25(+) regulatory T cells control the severity of viral immunoinflammatory lesions. J Immunol 2004, 172:4123-4132.
26. Thomson M, Nascimbeni M, Havert MB, et al.: The clearance of hepatitis C virus infection in chimpanzees may not necessarily correlate with the appearance of acquired immunity. J Virol 2003, 77:862-870.
27. Tseng CT, Klimpel GR: Binding of the hepatitis C virus envelope protein E2 to CD81 inhibits natural killer cell functions. J Exp Med 2002, 195:43-49.
28. Lucas M, Gadola S, Meier U, et al.: Frequency and phenotype of circulating Valpha24/Vbeta11 double-positive natural killer T cells during hepatitis C virus infection. J Virol 2003, 77:2251-2257.
29. Shata MT, Tricoche N, Perkus M, et al.: Exposure to low infective doses of HCV induces cellular immune responses without consistently detectable viremia or seroconversion in chimpanzees. Virology 2003, 314:601-616.
30. Post JJ, Pan Y, Freeman AJ, et al.: Clearance of hepatitis C viremia associated with cellular immunity in the absence of seroconversion in the hepatitis C incidence and transmission in prisons study cohort. J Infect Dis 2004, 189:1846-1855.
31. Bartosch B, Bukh J, Meunier JC, et al.: In vitro assay for neutralizing antibody to hepatitis C virus: evidence for broadly conserved neutralization epitopes. Proc Natl Acad Sci USA 2003, 100:14199-14204.
32. Lucas M, Karrer U, Lucas A, et al.: Viral escape mechanisms - escapology taught by viruses. Int J Exp Pathol 2001, 82:269-286.
33. Farci P, Shimoda A, Coiana A, et al.: The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies. Science 2000, 288:339-344.
34. Erickson AL, Kimura Y, Igarashi S, et al.: The outcome of hepatitis C virus infection is predicted by escape mutations in epitopes targeted by cytotoxic T lymphocytes. Immunity 2001, 15:883-895.
35. Abbate I, Cappiello G, Lo lacono O, et al.: Heterogeneity of HVR-1 quasispecies is predictive of early but not sustained virological response in genotype 1b-infected patients undergoing combined treatment with PEG- or STD-IFN plus RBV. J Biol Regul Homeost Agents 2003, 17:162-165.
36. Neumann AU, Lam NP, Dahari H, et al.: Hepatitis C viral dynamics in vivo and the antiviral efficacy of irtterferon-alpha therapy. Science 1998, 282:103-107.
37. Chang KM, Rehermann B, McHutchison JG, et al.: Immunological significance of cytotoxic T lymphocyte epitope variants in patients chronically infected by the hepatitis C virus. J Clin Invest 1997, 100:2376-2385.
38. Han JQ, Barton DJ: Activation and evasion of the antiviral 2′-5′ oligoadenylate synthetase/ribonuclease L pathway by hepatitis C virus mRNA. RNA 2002, 8:512-525.
39. Major ME, Mihalik K, Fernandez J, et al.: Long-term follow-up of chimpanzees inoculated with the first infectious clone for hepatitis C virus. J Virol 1999, 73:3317-3325.
40. Foy E, Li K, Wang CF, et al.: Regulation of interferon regulatory factor-3 by the hepatitis C virus serine protease. Science 2003, 300:1145-1148. Hepatitis C virus can sabotage the host antiviral response through directly blocking the activation of a key transcription factor in the IFN signaling pathway. Disruption of the viral NS3/4A serine protease function by a small molecule inhibitor relieved this blockade and restored the host IFN responses.
41. Blindenbacher A, Duong FH, Hunziker L, et al.: Expression of hepatitis c virus proteins inhibits interferon alpha signaling in the liver of transgenic mice. Gastroenterology 2003, 124:1465-1475.
42. Gale MJ Jr, Korth MJ, Tang NM, et al.: Evidence that hepatitis C virus resistance to interferon is mediated through repression of the PKR protein kinase by the nonstructural 5A protein. Virology 1997, 230:217-227.
43. Taylor DR, Shi ST, Romano PR, et al.: Inhibition of the interferon-inducible protein kinase PKR by HCV E2 protein. Science 1999, 285:107-110 [see comments].
44. Disson O, Haouzi D, Desagher S, et al.: Impaired clearance of virus-infected hepatocytes in transgenic mice expressing the hepatitis C virus polyprotein. Gastroenterology 2004, 126:859-872.
45. Lucas M, Vargas-Cuero AL, Lauer GM, et al.: Pervasive influence of hepatitis C virus on the phenotype of antiviral CD8+ T cells. J Immunol 2004, 172:1744-1753.
46. Large MK, Kittlesen DJ, Hahn YS: Suppression of host immune response by the core protein of hepatitis C virus: possible implications for hepatitis C virus persistence. J Immunol 1999, 162:931-938.
47. Joo M, Chianese-Bullock KS, Nguyen T, et al.: Suppression of IFN-g and IL-2 production in transgenic mice expressing the core protein of hepatitis C virus. In Immunology 2000. May 12-16, 2000; Seattle, Washington: The Federation of American Societies for Experimental Biology; 2000:A1038.
48. Sun JR, Bodola F, Fan XG, et al.: Hepatitis C virus core and envelope proteins do not suppress the host's ability to clear a hepatic viral infection. J Virol 2001, 75:11992-11998.
49. Liu ZX, Nishida H, He JW, et al.: Hepatitis C virus genotype 1b core protein does not exert immunomodulatory effects on virus-induced celluiar immunity. J Virol 2002, 76:990-997.
50. Herzer K, Falk CS, Encke J, et al.: Upregulation of major histocompatibility complex class I on liver cells by hepatitis C virus core protein via p53 and TAP1 impairs natural killer cell cytotoxicity. J Virol 2003, 77:8299-8309.
51. Konan KV, Giddings TH, Ikeda M, et al.: Nonstructural protein precursor NS4A/B from hepatitis C virus alters function and ultrastructure of host secretory apparatus. J Virol 2003, 77:7843-7855.
52. Diepolder HM: Interferon-[alpha] for hepatitis C: antiviral or immunotherapy? J Hepatol 2004, 40:1030-1031.
53. Hultgren C, Desombere I, Leroux-Roels G, et al.: Evidence for a relation between the viral load and genotype and hepatitis C virus-specific T cell responses. J Hepatol 2004, 40:971-978.
54. Ando K, Guidotti LG, Wirth S, et al.: Class I-restricted cytotoxic T lymphocytes are directly cytopathic for their target cells in vivo. J Immunol 1994, 152:3245-3253.
55. Sun JR, Stalls MA, Thompson KL, et al.: Cell cycle block in anergic T cells during tolerance induction. Cell Immunol 2003, 225:33-41.
56. Helbig KJ, Ruszkiewicz A, Semendric L, et al.: Expression of the CXCR3 ligand I-TAC by hepatocytes in chronic hepatitis C and its correlation with hepatic inflammation. Hepatology 2004, 39:1220-1229.
57. He XS, Rehermann B, Lopez-Labrador FX, et al.: Quantitative analysis of hepatitis C virus-specific CD8(+) T cells in peripheral blood and liver using peptide-MHC tetramers. Proc Natl Acad Sci USA 1999, 96:5692-5697.
58. Tseng CT, Miskovsky E, Houghton M, et al.: Characterization of liver T-cell receptor gamma delta T cells obtained from individuals chronically infected with hepatitis C virus (HCV): evidence for these T cells playing a role in the liver pathology associated with HCV infections. Hepatology 2001, 33:1312-1320.
59. Boisvert J, Kunkel EJ, Campbell JJ, et al.: Liver-infiltrating lymphocytes in end-stage hepatitis C virus: subsets, activation status, and chemokine receptor phenotypes. J Hepatol 2003, 38:67-75.
60. Bowen DG, Warren A, Davis T, et al.: Cytokine-dependent bystander hepatitis due to intrahepatic murine CD8 T-cell activation by bone marrow-derived cells. Gastroenterology 2002, 123:1252-1264.
61. Gremion C, Grabscheid B, Wolk B, et al.: Cytotoxic T lymphocytes derived from patients with chronic hepatitis C virus infection kill bystander cells via Fas-FasL interaction. J Virol 2004, 78:2152-2157.
62. Lanford RE, Guerra B, Chavez D, et al.: Cross-genotype immunity to hepatitis C virus. J Virol 2004, 78:1575-1581.
63. Inoue K, Sekiyama K, Yamada M, et al.: Combined interferon alpha2b and cyclosporin A in the treatment of chronic hepatitis C: controlled trial. J Gastroenterol 2003, 38:567-572. In patients with chronic hepatitis C, combined IFN and cyclosporin A treatment was more effective than IFN alone. The benefit was mostly achieved in patients with a high viral load and more IFN-resistant HCV genotype 1. No comparison with combined IFN and ribavirin was made in this study.
64. Zeuzem S, Carreno V: Interleukin-12 in the treatment of chronic hepatitis B and C. Antiviral Res 2001, 52:181-188.
65. Nelson DR, Lauwers GY, Lau JY, et al.: Interleukin 10 treatment reduces fibrosis in patients with chronic hepatitis C: a pilot trial of interferon nonresponders. Gastroenterology 2000, 118:655-660 [see comment].
66. Boonyarad V, Chutaputti A, Choeichareon S, et al.: Interspousal transmission of hepatitis C in Thailand. J Gastroenterol 2003, 38:1053-1059.
67. Lai KW, Young KC, Cheng PN, et al.: Interspousal transmission of hepatitis C virus: application of comparing the variability of HVR1 nucleotide region. Hepatogastroenterology 2004, 51:791-795.
68. Pham TN, MacParland SA, Mulrooney PM, et al.: Hepatitis C virus persistence after spontaneous or treatment-induced resolution of hepatitis C. J Virol 2004, 78:5867-5874. Using a more sensitive assay, the authors detected a low level of HCV replication years after apparent resolution of hepatitis C. These results may help to explain the persistence of HCV-specific T cells in "recovered" patients and chimpanzees, and further stress the importance of an uncompromised immune system in these individuals.